Content and data provided by various third parties and Fidelity - Terms of Use
Print.Print
Small font size A Larger text size A Largest text size A

Cogent Biosciences Prices $475 Million in Combined Equity, Convertible Notes Offerings

BY MT Newswires | CORPORATE | 11/12/25 05:39 AM EST

05:39 AM EST, 11/12/2025 (MT Newswires) -- Cogent Biosciences (COGT) said late Tuesday it has priced its public offering of 9.7 million shares at $31 per share and a concurrent $200 million offering of 1.625% convertible senior notes due 2031, for expected combined net proceeds of about $475.3 million.

The company said the equity portion was upsized from the previously announced $200 million.

Underwriters had been granted a 30-day option to purchase up to an additional 1.45 million shares and $30 million in convertible notes to cover over-allotments.

The equity offering is expected to close on Nov. 13, and the notes offering on Nov. 18, each subject to customary conditions, the company said.

It added that the convertible notes will mature on Nov. 15, 2031, with semi-annual interest payments beginning May 15, 2026.

Cogent said it plans to use proceeds to repay $50 million of existing term loan debt and fund development, regulatory, and commercialization activities for bezuclastinib and other pipeline candidates, along with general corporate purposes.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

More Fixed Income News

All Fixed Income News

In general the bond market is volatile, and fixed income securities carry interest rate risk. (As interest rates rise, bond prices usually fall, and vice versa. This effect is usually more pronounced for longer-term securities.) Fixed income securities also carry inflation risk and credit and default risks for both issuers and counterparties. Unlike individual bonds, most bond funds do not have a maturity date, so avoiding losses caused by price volatility by holding them until maturity is not possible.

Lower-quality debt securities generally offer higher yields, but also involve greater risk of default or price changes due to potential changes in the credit quality of the issuer. Any fixed income security sold or redeemed prior to maturity may be subject to loss.

Before investing, consider the funds' investment objectives, risks, charges, and expenses. Contact Fidelity for a prospectus or, if available, a summary prospectus containing this information. Read it carefully.

© 1998 – 2014 FMR LLC.

All rights reserved.
fir_news_article